Item 8.01 Other Events

On November 20, 2019, Aravive, Inc. (the "Company") issued a press release announcing new positive data from the ongoing Phase 1b portion of the Phase 1b/2 clinical trial of AVB-500 in platinum-resistant ovarian cancer patients. The data from the first 31 patients treated at the 10mg/kg dose level are maturing and affirm earlier findings on the relationship between AVB-500 levels and anti-tumor response. In this data analysis, high serum drug levels of AVB-500 were strongly predictive of anti-tumor activity with statistically significant correlation to progression free survival (PFS; p=0.0066). PFS is the primary endpoint for platinum-resistant ovarian cancer clinical trials. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The Company additionally updated its corporate presentation, a copy of which is attached as Exhibit 99.2 hereto and is incorporated herein by reference.

The press release attached as Exhibit 99.1 to this Current Report on Form 8-K and the corporate presentation attached as Exhibit 99.2 to this Current Report on Form 8-K include "safe harbor" language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are "forward-looking" rather than historical.

The Company undertakes no duty or obligation to update or revise information included in this Current Report on Form 8-K, the press release attached as Exhibit 99.1 hereto or the corporate presentation attached as Exhibit 99.2 hereto.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

The following exhibits are filed with this Current Report on Form 8-K:






Exhibit
Number    Description

99.1        Aravive, Inc. Press Release, dated November 20, 2019
99.2        Corporate Presentation, dated November 20, 2019

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses